Dr Lal PathLabs reports 16% rise in Q2 profit, declares ₹7 interim dividend and 1:1 bonus issue
Mumbai: Dr Lal PathLabs Limited reported consolidated revenue of ₹731 crore for the second quarter of FY2025–26, marking a 10.7% year-on-year increase, while profit after tax (PAT) rose 16.4% to Rs 152 crore with a net margin of 20.8%, the diagnostics major said in a statement on Thursday.
Dr Lal PathLabs profit stood at Rs 131 crore in the same quarter in the previous financial year.
The company’s EBITDA grew 10.8% during the quarter, maintaining a healthy margin of 30.7%.
The board also declared an interim dividend of ₹7 per share and approved a 1:1 bonus issue — one bonus share for every existing share held on the record date.
For the first half of FY26, revenue rose 11% year-on-year, underscoring steady growth across the company’s network of 298 laboratories, including national and regional reference labs in Delhi, Kolkata, Bengaluru, and Mumbai, along with over 6,600 patient service centres and 12,000 pickup points nationwide.
Dr Lal PathLabs said it continues to strengthen its diagnostic infrastructure and expand its reach, serving patients, hospitals, and corporate clients across India.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
